HomeALZN • NASDAQ
Alzamend Neuro Inc
add
Market news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Apr 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 1.14M | 33.98% |
Net income | -1.14M | -33.81% |
Net profit margin | — | — |
Earnings per share | -9.48 | 92.11% |
EBITDA | -1.13M | -34.50% |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Apr 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 3.95M | 950.04% |
Total assets | 4.60M | 628.80% |
Total liabilities | 634.76K | -80.32% |
Total equity | 3.97M | — |
Shares outstanding | 2.90M | — |
Price to book | 0.46 | — |
Return on assets | -64.87% | — |
Return on capital | -76.77% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Apr 2025info | Y/Y change |
|---|---|---|
Net income | -1.14M | -33.81% |
Cash from operations | -688.71K | 51.73% |
Cash from investing | -210.00K | — |
Cash from financing | 1.49M | -2.02% |
Net change in cash | 590.52K | 533.74% |
Free cash flow | -558.79K | 49.57% |
Previous close
$2.37
Day range
$2.33 - $2.46
Year range
$2.06 - $17.10
Market cap
7.41M USD
Avg Volume
95.34K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Founded
2016
Headquarters
Website
Employees
6
